OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
April 03, 2021
Accelerated formulation strategies are a useful tool to reduce development timelines and cost, but key priorities must be considered early on to ensure success.
April 02, 2021
In-vitro and in-silico tools can help predict in-vivo outcomes for low-solubility drugs formulated as spray-dried dispersions.
March 19, 2021
Hovione has successfully completed the Phase II clinical trial of its ophthalmic formulation of minocycline, Meizuvo.
March 03, 2021
Various strategies to improve bioavailability are being continuously evaluated, affording greater commercial prospects for the future.
March 02, 2021
FDA moves recommended timeline for API and drug manufacturers to assess impurity risks to March 31, 2021.
February 03, 2021
Plasma-based proteins and cell-based therapies have significant potential to address unmet medical needs.
Rapid growth in biologics and increasing complexity of new compounds are some of the factors driving development of innovative delivery solutions.
Viewpoint: Continued dialogue among pharma stakeholders is needed to achieve consensus regarding excipient composition.
January 03, 2021
The right partner can help companies overcome key formulation challenges for biologic drugs.
December 16, 2020
A newly developed polymer, DynaShield, may have the capability to ensure global access for COVID-19 treatment and prevention.